Invex Therapeutics
About:
Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment.
Website: https://invextherapeutics.com/
Description:
Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury.
Total Funding Amount:
$26M
Headquarters Location:
Subiaco, Western Australia, Australia
Founded Date:
2019-01-01
Contact Email:
info(AT)invextherapeutics.com
Founders:
Alexandra Sinclair, Jason Loveridge
Number of Employees:
1-10
Last Funding Date:
2020-05-22
IPO Status:
Public
Industries:
© 2025 bioDAO.ai